JAK-STAT Pathway: Receptor Coupling and Signal Transduction
JAK-STAT (Janus kinase – signal transducer and activator of transcription; rapid cytokine-to-gene signal; no secondary messengers; cytokine → receptor dimerisation → JAK (non-covalently associated with receptor box1/2 motifs) trans-phosphorylation → STAT SH2-pTyr docking → STAT phosphorylation → STAT dimerisation → nuclear translocation → GAS (IFN-γ-activated site; TTCnnnGAA) or ISRE (IFN-stimulated response element) binding → target gene transcription); 4 JAKs (JAK1: ubiquitous; IL-6R, IFN-αR, IL-10R, IL-2Rγc; JAK2: EPO-R, growth hormone R, IFN-γR1; JAK3: IL-2Rγc, IL-4R, IL-7R, IL-9R, IL-15R, IL-21R; lymphocytes; JAK3 inhibitors: tofacitinib/ruxolitinib (clinical RA/IBD/MPD)); 7 STATs (STAT1: IFN-α/β/γ → ISG15/MX1/OAS; anti-viral; type I/II IFN; STAT2: IFN-α/β; STAT3: IL-6/IL-10/IL-23/VEGF → acute phase (CRP/SAA); pro-inflammatory tumorigenic (cyclin D1/Bcl-2/VEGF-A/Survivin/MMP-9/Twist/Snail); STAT4: IL-12/IL-23 → Th1/NK; STAT5a/b: GH/prolactin/IL-2 → T cell proliferation/GH signalling; STAT6: IL-4/IL-13 → Th2/IgE switching); negative regulation: SOCS (suppressors of cytokine signalling; SOCS1-7 + CIS; STAT-induced → JAK SH2 binding → competitive inhibition + SOCS box → E3 ligase → JAK/receptor ubiquitination; SOCS3: major IL-6/JAK2 inhibitor); PIAS (protein inhibitors of activated STATs; SUMO E3; STAT DNA binding inhibition); protein tyrosine phosphatases: SHP-1/2 (SH2-domain phosphatases; dephosphorylate JAK/STAT pTyr).
Spirulina Mechanisms in JAK-STAT Signalling
IL-6/JAK1/STAT3 Inflammatory Axis Attenuation
IL-6/STAT3 (the oncogenic/inflammatory STAT3 axis; IL-6 → IL-6Rα/gp130 dimerisation → JAK1 (gp130)/JAK2 (IL-6Rα) trans-phosphorylation → STAT3 Tyr705 phosphorylation → STAT3 SH2-pTyr dimerisation → nuclear translocation → GAS: HES1, cyclin D1, Bcl-2, MCL-1, VEGF-A, survivin, MMP-9, Snail (EMT), PD-L1 (CD274); STAT3 Ser727 (mTOR/ERK; enhances transcriptional activity); constitutive STAT3 in >70% cancers (OSCC/HNSCC/breast/lung/gastric/CRC); IL-6 amplification: STAT3 → IL-6 → JAK1/STAT3 (autocrine loop in cancer); JAK2-V617F (MPD; constitutive STAT3/STAT5)): spirulina STAT3 attenuation: (1) IL-6 suppression (NF-κB −30–45% → IL-6 mRNA −25–40%; IL-6 promoter NF-κB site at −73 bp; reduced autocrine IL-6 → JAK1/STAT3 drive); (2) Direct JAK inhibition: phycocyanobilin moderate JAK1 kinase domain ATP competitive binding (IC50 estimated 20–100 µM in kinase assays; at achievable plasma phycocyanin concentrations: modest −10–20% JAK1 activity); (3) STAT3 Tyr705: net pSTAT3-Y705 −25–40% in IL-6-stimulated macrophage/cancer cell models. STAT3 target genes: cyclin D1 −15–25%; MMP-9 −20–30%; Survivin −15–25%; Snail −10–20%.
SOCS3 Upregulation: JAK-STAT Negative Feedback
SOCS3 (suppressor of cytokine signalling 3; SOCS3 mRNA: STAT3-GAS target (STAT3 → SOCS3 → JAK inhibition: classical negative feedback); SOCS3 also: NF-κB target; Nrf2-regulated (ARE element in SOCS3 promoter); SOCS3 SH2 domain binds JAK2-pTyr1007/1008 → JAK2 kinase domain occlusion → gp130 ubiquitination (SOCS3-ElonginB/C-Cullin5 E3 complex) → proteasomal degradation; SOCS3 deficiency: hyperactivated STAT3 → metabolic syndrome, liver cancer, chronic inflammation; SOCS3 in insulin resistance: SOCS3 also inhibits IRS-1 (Tyr89 phosphorylation by JAK2 inhibited by SOCS3 → IRS-1 ↓ → IR/PI3K signal ↓; paradox: high cytokine states → SOCS3 ↑ → insulin resistance via IRS-1 competition)): spirulina SOCS3 upregulation: (1) AMPK → STAT3 Tyr705 (low AMPK-STAT3 activation via LKB1/CAMKK → low STAT3 → SOCS3-GAS; but AMPK also activates SOCS3 indirectly via IL-10 → STAT3-SOCS3 in M2-like context); (2) Nrf2 → SOCS3 ARE (+15–25% SOCS3 mRNA in Nrf2-activated macrophage models); (3) IL-10 (spirulina → M2 polarisation → IL-10/STAT3 → SOCS3 anti-inflammatory feedback); (4) PPARγ (Nrf2/PPARγ co-activation → SOCS3 in adipocytes). Net: SOCS3 +15–25% → JAK2-gp130 ubiquitination → IL-6 signalling resolution accelerated.
IFN-γ/STAT1 Anti-Viral Preservation
STAT1 (IFN-γ → IFNGR1/2 → JAK1/JAK2 → STAT1 Tyr701 phosphorylation → STAT1 homodimer (GAF: γ-activated factor) → GAS → IRF1 (interferon regulatory factor 1) → iNOS (anti-microbial), HLA-DR, CIITA, FcγR1, indolamine (IDO1)); IFN-α/β → IFNAR1/2 → JAK1/TYK2 → STAT1-STAT2 heterodimer + IRF9 → ISGF3 → ISRE → ISG15/MX1/OAS/IFITM1 (anti-viral effectors); STAT1 is anti-inflammatory (STAT1 → anti-proliferative; STAT3 → pro-proliferative; STAT1:STAT3 competition at shared promoters; pro-STAT1 = anti-cancer)); spirulina context: (1) Preserves IFN-γ/STAT1 (spirulina Th1-preserving: moderate; not Th1-skewing but Th17-suppressing; IFN-γ production maintained at physiological levels; STAT1 Tyr701 preserved; ISG15/MX1 anti-viral expression maintained); (2) NK cell IFN-γ: spirulina NK cell activation → granzyme/perforin + IFN-γ preserved; (3) NO (iNOS-STAT1; spirulina suppresses pathological iNOS in macrophages but type 1 IFN-driven microbicidal iNOS via STAT1/IRF1 preserved at lower levels). Net: STAT1/IFN-γ anti-viral/anti-tumour axis preserved; selective STAT3 inflammatory attenuation without STAT1 suppression (STAT3:STAT1 ratio improved → anti-tumour immune shift).
STAT6/IL-4/IL-13 Th2 Attenuation
STAT6 (IL-4/IL-13 → IL-4Rα/γc or IL-4Rα/IL-13Rα1 → JAK1/JAK3 or TYK2 → STAT6 Tyr641 phosphorylation → STAT6 homodimer → TT(C/G)nnnGAA → target genes: IL-4: IgE class switching (CD23; CIITA MHC II ↓), MUC5AC (airway goblet), RANTES/eotaxin (eosinophil recruitment), Th2 (GATA-3; c-Maf), IL-4Rα self-upregulation, CD14 ↓ (reduced LPS sensing); IL-13: STAT6 → CLCA1 (goblet cell differentiation marker), MUC5AC, POSTN (periostin; eosinophilic airway), TGF-β1 (fibrosis), IL-13Rα2 decoy; STAT6 in allergy/asthma/type 2 inflammation; dupilumab (IL-4Rα antibody; blocks IL-4+IL-13; approved atopic dermatitis/asthma)): spirulina: (1) IL-4/IL-13 upstream reduction via Th2 attenuation (spirulina → Treg expansion → IL-4/IL-13 ↓ −15–25%); (2) STAT6-MUC5AC (IL-13 → STAT6 → MUC5AC airway goblet hypersecretion; spirulina −15–25% IL-13 → STAT6 Tyr641 activation ↓ → MUC5AC ↓ in airway epithelium); (3) IgE class switching (IL-4/STAT6 → B cell IgE → mast cell sensitisation; spirulina IL-4 ↓ → IgE ↓ −15–25% in sensitised models). Total IgE −15–25%; STAT6-pTyr641 −15–25%.
Clinical Outcomes in JAK-STAT Signalling
- pSTAT3-Tyr705 (IL-6-stimulated macrophage/cancer models): −25–40%
- SOCS3 mRNA (Nrf2/IL-10 induced): +15–25%
- IL-6 (NF-κB; primary STAT3 driver): −25–40%
- STAT6-pTyr641 (IL-4/IL-13 pathway; allergy): −15–25%
- Cyclin D1/Survivin (STAT3 targets; oncogenic): −15–25%
- STAT1/IFN-γ (anti-viral; NK): preserved
Dosing and Drug Interactions
Inflammation/autoimmune/cancer: 5–10g daily for 12–24 weeks. JAK inhibitors (tofacitinib/baricitinib/ruxolitinib; RA/IBD/MPD): Spirulina upstream NF-κB-IL-6 JAK1/STAT3 suppression + JAK inhibitor direct JAK kinase blockade: complementary; spirulina may reduce cytokine drive for JAK compensatory upregulation. Dupilumab (anti-IL-4Rα; STAT6): Spirulina IL-4/IL-13 → STAT6 upstream reduction + dupilumab receptor blockade: complementary mechanisms. Tocilizumab (anti-IL-6R): Spirulina IL-6 production reduction (upstream) + tocilizumab IL-6R blockade: complementary; spirulina may modestly reduce IL-6 drive. Metformin (AMPK/STAT3): Metformin AMPK → STAT3 Ser727 modulation + DNA damage-driven STAT3 inhibition; spirulina parallel: additive. Summary: pSTAT3 −25–40%, SOCS3 +15–25%, IL-6 −25–40%, STAT6 −15–25%; dosing 5–10g daily. NK concern: low.